AffyImmune Therapeutics Revenue and Competitors

Natick, MA

Location

$28.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AffyImmune Therapeutics's estimated annual revenue is currently $2.6M per year.(i)
  • AffyImmune Therapeutics's estimated revenue per employee is $77,500
  • AffyImmune Therapeutics's total funding is $28.9M.

Employee Data

  • AffyImmune Therapeutics has 33 Employees.(i)
  • AffyImmune Therapeutics grew their employee count by 38% last year.

AffyImmune Therapeutics's People

NameTitleEmail/Phone
1
SVP CMCReveal Email/Phone
2
SVP, Head Clinical DevelopmentReveal Email/Phone
3
VP Clinical OperationsReveal Email/Phone
4
SVP Operations and Business DevelopmentReveal Email/Phone
5
Head CMCReveal Email/Phone
6
CMC Logistics ManagerReveal Email/Phone
7
Research Associate Reveal Email/Phone
8
Senior ScientistReveal Email/Phone
9
Finance & OperationsReveal Email/Phone
10
Senior ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is AffyImmune Therapeutics?

Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.

keywords:N/A

$28.9M

Total Funding

33

Number of Employees

$2.6M

Revenue (est)

38%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AffyImmune Therapeutics News

2022-04-06 - AffyImmune Therapeutics to Present Poster at American ...

NATICK, Mass., April 6, 2022 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.6M336%$45M
#2
$6.2M343%N/A
#3
$3.9M34N/AN/A
#4
$7M35-3%N/A
#5
$2.8M356%N/A